Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
2.
Blood ; 86(6): 2343-9, 1995 Sep 15.
Article in English | MEDLINE | ID: mdl-7662980

ABSTRACT

Using Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) as a model, our aim has been to develop a molecular cytogenetic method of high resolution analysis for monitoring the frequency of cells with nonrandom chromosome rearrangements in the bone marrow of patients receiving treatment for hematologic malignancies. Long-term exposure (24 hours) of bone marrow cultures to colcemid (0.1 microgram/mL) maximized a high frequency of metaphase collection. Such preparations were subjected to fluorescence in situ hybridization (FISH) using a 5 Mb probe that overlapped the region of the translocation at chromosome 9q34. This detected the Ph translocation in the resultant large number of overly contracted chromosome spreads. The procedure was validated and verified by studying 70 double-blind marrow samples from patients in different stages of Ph+ CML and from patients with Ph- hematologic malignancies (controls). This hypermetaphase FISH (HMF) method clearly identified Ph+ metaphases and allowed the analysis of 500 hypermetaphases per sample in less than 1 hour after FISH. HMF (1) identified statistically significant differences between the frequencies of Ph+ cells in samples that differed by less than 4%; (2) resolved such differences among patient samples that were all judged 100% Ph+ by standard G-band cytogenetics (CG); (3) resulted in the reclassification of response status in 23% of the patients initially classified by CG; (4) recognized Ph+ cells in 16% of patients characterized as having a complete cytogenetic response and in one patient with an original diagnosis of Ph- CML; and in one patient with an original diagnosis of Ph- CML; and (5) was informative where insufficient metaphases were obtainable for analysis by CG. HMF appears to be uniquely suitable for monitoring the status of patients with CML receiving treatment. It should also be applicable for patients with any hematologic diseases where chromosomal alterations are known and appropriate FISH probes are available.


Subject(s)
Bone Marrow Examination/methods , In Situ Hybridization, Fluorescence/methods , Karyotyping/methods , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/pathology , Metaphase , Philadelphia Chromosome , Azure Stains , Bone Marrow/pathology , Chromosome Banding , Demecolcine/pharmacology , Humans , Immunologic Factors/therapeutic use , Interferon-alpha/therapeutic use , Leukemia/pathology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Metaphase/drug effects , Neoplasm, Residual , Single-Blind Method , Treatment Outcome , Tumor Cells, Cultured/drug effects
3.
Blood ; 83(8): 2268-73, 1994 Apr 15.
Article in English | MEDLINE | ID: mdl-8161793

ABSTRACT

Fluorescence in situ hybridization (FISH) probe for the identification of the Philadelphia (Ph) translocation [t(9;22) (q34;q11)] in chronic myelogenous leukemia cells was developed by inter-Alu-polymerase chain reaction of DNA from an interspecific somatic cell hybrid containing approximately 5 Mb of human DNA covering the ABL gene region on human chromosome 9q34. This probe was large enough to be effective in identifying the genomic domains yet small enough to resolve them in more than 90% of bone marrow interphase cells. Combination of the probe with a cosmid contig probe for the BCR region of chromosome 22 in two-color FISH reduced the frequency of false-positive identification of the Ph chromosome to less than 1%. The procedure allows detection of as few as 1% Ph+ cells independent of the cycling status or BCR/ABL expression level of cells, and the quantitation of non-Ph chromosome-containing interphase nuclei in the marrow of patients judged 100% Ph+ by standard cytogenetics.


Subject(s)
Interphase , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Philadelphia Chromosome , Protein-Tyrosine Kinases , Humans , Hybrid Cells , In Situ Hybridization, Fluorescence , Polymerase Chain Reaction , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins c-bcr
4.
Am J Clin Oncol ; 16(2): 105-8, 1993 Apr.
Article in English | MEDLINE | ID: mdl-8452099

ABSTRACT

A 37-year-old woman with chronic myelogenous leukemia underwent allogeneic bone marrow transplantation with CD8-depleted marrow from an HLA-identical sister. On day 43 post-transplant, the patient developed a headache and became lethargic and tremulous. Magnetic resonance imaging (MRI) of the brain showed abnormal meningeal and superficial parenchymal enhancement anteriorly. The spinal fluid had an elevated protein level with normal glucose and a neutrophilic pleocytosis. At autopsy, Toxoplasma meningoencephalitis was seen. On review of the literature, headache and confusion at 1-2 months post-transplant are common presenting signs of central nervous system toxoplasmosis. The predominance of neutrophils in the spinal fluid in this patient probably reflects the meningeal component of the infection and is an unusual finding. The presentation of toxoplasmosis in marrow transplant recipients is quite pleomorphic, and a definite diagnosis is difficult to obtain antemortem. Empiric therapy with pyrimethamine and sulfadiazine should be considered for marrow transplant recipients with neurologic deficits for which there is no other apparent etiology.


Subject(s)
Bone Marrow Transplantation/adverse effects , Meningoencephalitis/etiology , Meningoencephalitis/microbiology , Toxoplasmosis/etiology , Adult , Central Nervous System Diseases/diagnosis , Central Nervous System Diseases/microbiology , Female , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/surgery , Meningoencephalitis/diagnosis , Toxoplasmosis/diagnosis , Transplantation, Homologous
6.
J Interferon Res ; 12(5): 323-7, 1992 Oct.
Article in English | MEDLINE | ID: mdl-1431311

ABSTRACT

Interferon-alpha (INF-alpha) induces cytogenetic remissions in 20% of chronic myelogenous leukemia (CML) patients. To clarify the mechanisms through which this antiproliferative action of IFN is mediated in the CML cell, a modification of the mobility-shift assay was used to follow the formation of complexes between nuclear proteins and IFN-inducible transcriptional enhancers involved in mediating the cellular effects of IFN-alpha. These studies identified a complex that was present in the myeloid cells of 18/24 (75%) of chronic-phase CML patients tested whose cells contained 100% Philadelphia chromosome positive (Ph+) cells, while the proteins of none of the samples tested from normal peripheral blood samples and only 22% (2/9) of the CML patients in an IFN-induced major cytogenetic remission (less than 30% Ph+ cells) contained these complexes. These studies suggest that the mobility-shift assay detects changes in the CML myeloid cell that distinguish it from the normal myeloid cell.


Subject(s)
Enhancer Elements, Genetic/drug effects , Gene Expression Regulation, Neoplastic/drug effects , Interferon-alpha/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/therapy , Nuclear Proteins/chemistry , Transcription, Genetic/drug effects , Base Sequence , Enhancer Elements, Genetic/genetics , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Molecular Sequence Data , Reference Values , Remission Induction/methods , Transcription, Genetic/genetics
7.
J Clin Invest ; 86(5): 1664-70, 1990 Nov.
Article in English | MEDLINE | ID: mdl-2243138

ABSTRACT

Cytoplasmic protein from peripheral blood myeloid cells of chronic myelogenous leukemia (CML) patients altered the electrophoretic mobility of complexes formed between nuclear proteins and interferon-inducible transcriptional enhancers. Immature myeloid marrow cells (blasts and promyelocytes) have a higher level of this activity than do mature myeloid marrow cells (bands and polys). This activity, which is not detectable in the peripheral blood cells of normal individuals, is at least 50-fold higher in CML marrow blasts and promyelocytes than that found in marrow blasts and promyelocytes of normal individuals. This activity was inhibited by in vivo incubation of immature myeloid cells with the phosphatase inhibitor, sodium orthovanadate (0.2 mM), and by adding orthovanadate (20 mM) directly to cytoplasmic proteins of myeloid cells. Interferon-alpha (1,000 U/ml) reduced the effects of the CML myeloid cell cytoplasmic protein on the electrophoretic mobility of nuclear protein-DNA complexes. These data suggest that a unique phosphatase may be involved in the abnormalities in CML which are modulated by interferon-alpha.


Subject(s)
Acid Phosphatase/blood , Enhancer Elements, Genetic , Gene Expression Regulation, Neoplastic , Interferon Type I/pharmacology , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/enzymology , Nuclear Proteins/metabolism , Base Sequence , Bone Marrow/pathology , Electrophoresis , Humans , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/blood , Leukemia, Myelogenous, Chronic, BCR-ABL Positive/genetics , Molecular Sequence Data , Temperature , Transcription, Genetic
8.
J Biol Chem ; 263(35): 19043-7, 1988 Dec 15.
Article in English | MEDLINE | ID: mdl-3143722

ABSTRACT

The present study was undertaken to determine the mechanism by which phorbol ester stimulates eicosanoid synthesis in endothelial cells. We observed that phorbol 12-myristate 13-acetate (PMA) actively stimulated eicosanoid synthesis over a prolonged period of time, and the stimulatory effect was abolished by cycloheximide and actinomycin D. Western blot was employed to test the hypothesis that PMA elicited sustained eicosanoid synthesis via the stimulation of de novo synthesis of prostaglandin G/H synthase (cyclooxygenase, EC 1.14.99.1). Treatment of cultured human umbilical vein endothelial cells resulted in an enhancement of the 70-kDa immunoreactive prostaglandin G/H synthase band over the control cells treated with medium alone. The enhancement was abolished by cycloheximide. Human umbilical vein endothelial cells were then metabolically labeled with L-[35S]methionine, and the effect of PMA on methionine incorporation was evaluated by immunoblotting. PMA increased the synthetic rate of prostaglandin G/H synthase over the control cells. By pulse-chase experiments, we further showed that prostaglandin G/H synthase has a rapid turnover rate (t1/2 less than 10 min) in control cells, and PMA had no effect on the enzyme turnover. Our data indicate that PMA increases the synthesis of prostaglandin G/H synthase which is required for circumventing the autoinactivation of prostaglandin G/H synthase and hence permit sustained conversion of arachidonic acid into eicosanoids.


Subject(s)
Endothelium/drug effects , Prostaglandin-Endoperoxide Synthases/biosynthesis , Tetradecanoylphorbol Acetate/pharmacology , Cells, Cultured , Chromatography, High Pressure Liquid , Cycloheximide/pharmacology , Dactinomycin/pharmacology , Endothelium/enzymology , Epoprostenol/biosynthesis , Humans , Methionine/pharmacokinetics , Molecular Weight , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...